NO942241L - - Google Patents

Info

Publication number
NO942241L
NO942241L NO942241A NO942241A NO942241L NO 942241 L NO942241 L NO 942241L NO 942241 A NO942241 A NO 942241A NO 942241 A NO942241 A NO 942241A NO 942241 L NO942241 L NO 942241L
Authority
NO
Norway
Prior art keywords
day
bisphosphonate
parathyroid hormone
administered
administration regimen
Prior art date
Application number
NO942241A
Other languages
English (en)
Norwegian (no)
Other versions
NO942241D0 (no
Inventor
Ann Dunbar Geddes
Rogely Waite Boyce
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of NO942241D0 publication Critical patent/NO942241D0/no
Publication of NO942241L publication Critical patent/NO942241L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO942241A 1991-12-17 1994-06-15 Fremgangsmåte for behandling av osteoporose ved behandling av bisfosfonater og parathyreoideahormon NO942241D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17
PCT/US1992/010869 WO1993011786A1 (en) 1991-12-17 1992-12-15 Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Publications (2)

Publication Number Publication Date
NO942241D0 NO942241D0 (no) 1994-06-15
NO942241L true NO942241L (enExample) 1994-08-09

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942241A NO942241D0 (no) 1991-12-17 1994-06-15 Fremgangsmåte for behandling av osteoporose ved behandling av bisfosfonater og parathyreoideahormon

Country Status (18)

Country Link
US (1) US5616560A (enExample)
EP (1) EP0618805A1 (enExample)
JP (1) JPH07502507A (enExample)
AU (2) AU3322593A (enExample)
BR (1) BR9206941A (enExample)
CA (1) CA2124792C (enExample)
CZ (1) CZ282889B6 (enExample)
FI (1) FI942884A7 (enExample)
HU (1) HUT68010A (enExample)
IL (1) IL104108A (enExample)
MA (1) MA23079A1 (enExample)
MX (1) MX9207349A (enExample)
NO (1) NO942241D0 (enExample)
NZ (1) NZ246456A (enExample)
RU (2) RU2112515C1 (enExample)
SK (1) SK74594A3 (enExample)
WO (1) WO1993011786A1 (enExample)
ZA (1) ZA929758B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
EP0779812A4 (en) * 1994-09-09 1997-09-10 Procter & Gamble Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
JPH10505091A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
JP3796693B2 (ja) * 1994-12-28 2006-07-12 ガドール エス アー オルパドロネートからなる骨塊同化組成物
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
DK1635875T3 (da) * 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
AU2004264899A1 (en) * 2003-08-06 2005-02-24 Innophos, Inc. Method for promoting bone growth
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
CA2687903C (en) * 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CN104072606B (zh) * 2007-08-01 2017-09-22 总医院有限公司 利用g蛋白偶联受体和相关组合物的筛选方法
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза

Also Published As

Publication number Publication date
AU3322593A (en) 1993-07-19
FI942884L (fi) 1994-06-16
RU2112515C1 (ru) 1998-06-10
CA2124792C (en) 2000-07-04
MA23079A1 (fr) 1993-07-01
CZ282889B6 (cs) 1997-11-12
CZ147794A3 (en) 1994-12-15
RU94031209A (ru) 1996-07-27
WO1993011786A1 (en) 1993-06-24
AU663348B2 (en) 1995-10-05
CA2124792A1 (en) 1993-06-24
MX9207349A (es) 1993-12-01
FI942884A0 (fi) 1994-06-16
IL104108A (en) 1999-09-22
HUT68010A (en) 1995-05-29
US5616560A (en) 1997-04-01
NO942241D0 (no) 1994-06-15
RU2104699C1 (ru) 1998-02-20
IL104108A0 (en) 1993-05-13
ZA929758B (en) 1993-09-10
SK74594A3 (en) 1995-01-12
FI942884A7 (fi) 1994-06-16
HU9401798D0 (en) 1994-09-28
BR9206941A (pt) 1995-05-02
NZ246456A (en) 1997-03-24
AU3022692A (en) 1993-06-24
JPH07502507A (ja) 1995-03-16
EP0618805A1 (en) 1994-10-12

Similar Documents

Publication Publication Date Title
NO942241L (enExample)
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
Köle Results, experience, and problems in the operative treatment of anomalies with reverse overbite (mandibular protrusion)
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR950702121A (ko) 포스포네이트 및 비스테로이드계 소염 약물(nasid)을 함유하는 관절염 치료 조성물(compositions for the treatment of arthritis containing phosphonates and nsaids)
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
DK1201241T3 (da) Sammensætninger indeholdende capsaicin eller capsaicinanaloge og et bedøvelsesmiddel
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
Law et al. The effect of calcium hydroxide on deep carious lesions
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
NO945058L (no) Anvendelse av fosfonater for behandling av osteoporose
DK0539465T3 (da) Anvendelse af 20(R)-22-oxa-D-vitamin-analoger til fremstilling af et farmaceutisk præparat til behandling og/eller forebyggelse af hudaldring
SE8700157L (sv) Sett att forhindra kvicksilverforgiftning orsakad av upplosning av kvicksilver ur amalgamplomber samt komposition herfor
Cheraskin Roentgenographic manifestations of osseous changes in the jaws
AR001226A1 (es) Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця